Company: PFSA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004396
Chunk: 1300

Company: Profusa, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9
Chunk 1300
---
, and was chairman of the audit committee from August 2005 until December
2015. From June 2016 to December 2016, Mr. Stover was chairman of the audit committee and a member of the board of directors of Viatar
CTC Solutions, Inc. From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly
held specialty pharmaceutical company (current market cap of ~$700M) then listed on the American Stock Exchange. In addition to other
relevant experience, Mr. Stover was also formerly a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the bioscience
industry division in New Jersey. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.
We believe that Mr. Stover is well-qualified to serve as a director of our company based on Mr. Stover’s experience holding senior
leadership positions in the life sciences industry, and his specific experience and skills in the areas of general operations, financial
operations and administration.

Fred Knechtel - Co-Founder, Director and Chief
Financial Officer

Fred Knechtel has served as
our Chief Financial Officer and director since inception. From August 2022 to August 2023, Mr. Knechtel served as chief financial officer
of DiamiR Biosciences. From January 2020 to January 2021, Mr. Knechtel served as chief financial officer of Interpace Biosciences, Inc.
From June 2018 to December 2018, Mr. Knechtel served as chief financial officer of GENEWIZ, Inc. From November 2014 to November 2017,
Mr. Knechtel served as group chief financial officer of Sims Metal Management. From November 2009 to October 2014, Mr. Knechtel served
as chief financial officer of Remy International, Inc. Mr. Knechtel received a Bachelor of Engineering from Stony Brook University and
a M.B.A in Finance from Hofstra University. We believe that Mr. Knechtel is well-qualified to serve as a director of our company based
on Mr. Knechtel’s experience holding high level executive positions in the life sciences industry, and his financial and accounting
experience.

Peter O’Rourke - Chairman of the Board

Peter